(Sharecast News) - AstraZeneca on Monday reported mixed regulatory and clinical news, with its breast cancer drug Enhertu securing a US breakthrough therapy designation in early disease, while a late-stage lung cancer trial of ceralasertib in combination with Imfinzi failed to meet its primary survival endpoint.
The FTSE 100 pharmaceutical giant...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE